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THE LEGACY OF GERALD KLERMAN
As a clinical researcher with a life-time concern with treatment, Gerald Klerman was ahead of his time in attempting to integrate diverse approaches to under standing psychiatric disorders and their treatment (Kler man 1975) . This notion of integration extended to the development of etiologic theories. His legacy is one that clearly demonstrates an interest in a wide range of psy chiatric problems for which he always sought innova tive solutions. His most important principle was that all of our work -basic, preclinical, and clinical-needed a strong empirical basis. He played a major role in the psychopharmacologic revolution and provided an im portant sobering balance during the early years of com munity psychiatry. His initial interests ranged from and current stressors is reviewed, as well as biologic pathways and correlates. Finally, using treatment outcome as a window on pathogenesis is suggested as a strategy for understanding the interaction of biologic and psychosocial parameters in the onset of and recovery from episodes of depressive illness.
[Neuropsychopharmacology 9: 169-180, 1993J schizophrenia to affective disorders. When he moved from Yale University to Harvard College, he continued several sets of collaborative studies with Dr. Myrna Weissman that ultimately led to a greater understand ing of the long-term course of mood disorders as well as to the development and implementation of a major form of psychotherapy known as interpersonal psy chotherapy (IPT) (Klerman 1983; Klerman et al. 1984) .
The collaborative depression studies sponsored by the National Institutes of Mental Health (NIMH) in which he was a principal investigator have produced numerous insights in our understanding of personal ity, genetics, psychopathology, and the long-term prog nosis of the serious mood disorders. The emphasis on longitudinal studies was also reflective of his interest in disorders across the life cycle. As a teacher, he provided inspiration for students and a role model for young investigators. He was an ombudsman for clini cal researchers, with particular emphasis on quality.
While Dr. Klerman was always a model of personal courage, he also demonstrated extraordinary intellec tual courage. This, in turn, allowed him to show ap propriate levels of skepticism while encouraging inves tigators to maintain their convictions until disproven.
He sought to facilitate treatment research at NIMH and elsewhere, setting standards for multisite collaborative studies, whether they were sponsored by federal agen cies or by the pharmaceutical industry. Indeed, he led the way in developing intellectual dialogue with the 0893-133X/93/$6.00 pharmaceutical industry. His interest in treatment re search and his notion that demonstrated efficacy should provide the basis for public policy stimulated his own interest in the translation of scientiftc knowledge to pub lic policy.
As we wrestle in the 1990s with immediate concerns that are scientifIc, economic, and political, we need to remember that Gerald Klerman would push us to work on the future, to work on new opportunities, and to be aware of our limitations while seeking to remove im pediments (Klerman 1990) . It is to his most important contribution to psychiatry that this lecture is dedicated. Because he was my frr st clinical supervisor as a psy chiatric resident, it would only be consistent ii my lec ture were to focus on the mission of thel' apeutics and models of research that will help us with this mission.
My own interest in treatment has always been mixed with a parallel interest in psychobiology. While I have been interested in the pathogenesis of disorders, I have also been concerned about the relationship of pathogenesis to treatment and prognosis. The strate gies developed by Gerald Klerman have provided much of the intellectual climate in which it has been possible to integrate biology and treatment. Early on, many of us emphasized so-called cross-sectional research, stud ies limited to the episode of illness. Later, we came to understand the importance of following individuals lon gitudinally to understand the disorder fully. This has provided a strong stimulus to develop longitudinal de signs. However, the ideal longitudinal study cannot be conducted by beginning with subjects in whom the dis order has already developed. Due to an interest in ill ness trajectories and pathways to the onset of disorders, perhaps this lecture should be subtitled "The Road to Depression" because we will review models that pro vide an integrated view of vulnerability factors from both psychosocial and biologic domains. Such models may help us to understand how, after the illness be gins, we can provide interventions that improve our level of treatment efficacy. Thus, the reason for empha sis on those events and changes that occur long before the disorder becomes apparent.
VARYING PATHWAYS TO DEPRESSION
Most scientists today would concur that one needs to consider at least two strands of investigative activity that might provide important insights regarding path ways to depression. One strand is often characterized as representing biologic genetic domains and the other representing psychosocial/environmental domains. The balance between vulnerability and protective fac tors in each of these domains and across domains is not completely known. One school of thought argues that provoking agents in the environment (in the form of NEUROPSYCHOPHARMACOLOGY 1 99 stressful life events and chronic difficulties) is a major determinant of what leads an individual with the right set of vulnerability factors to develop an onset of depres sion (Brown and Harris 1978) . Other researchers do not subscribe to the provoking agent model, viewing the risk factors as exclusively biologic in nature. My own view is that both biologic/genetic factors and the psy· chosocial/ environmental factors play a role in the path way to depression. Finally, in disorder in which females predominate by a ratio of at least 2: 1, the role of gender must be integrated into any explanatory model. Given the complexity of this issue, the reader is directed to a recent review of this important issue (Frank, su� mitted) .
With respect to those biologic/genetic areas that traditionally attract investigative talent, at least three major areas should be included: (1) biological clocks or rhythms, (2) the neurobiology of stress, and (3) tern· perament (Moore 1991) . A number of researchers be lieve that even at an early stage of development, insta bility with respect to biologic rhythms (which coul d be reflected as a developmental lag in the biologic clock), may represent a vulnerability factor for the develop ment of clinical depression. In a similar vein, research· ers involved in stress physiology and reactivity point to data in childhood and adolescence, as well as in young adults that support the idea that such measures may reflect vulnerability factors for the onset of depres sion. In the area of temperament, highly heritable traits such as shyness and negative self-evaluation kindled the interest of numerous investigators (Kagan et al. 1988; Kagan and Snidman 1991a) . Indeed, Kagan and colleagues (Kagan and Snidman 1991b) have sought to integrate behavioral data with measures of physiologic stress observed in children with very high levels of s0-cial inhibition. However, up to now relatively few groups have sought to integrate the diverse areas that are representative of the biologic/genetic domain. Re cently, there has been some interest in examining young infants who may be at later risk for affective disorders (Dawson et al. 1992a (Dawson et al. , 1992b .
On the other hand, a considerable body of litera· ture has been written to demonstrate that early develop mental experiences are key, perhaps necessary, ingre dients in the later development of depression. One research group has categorized such experiences un· der the rubric of childhood adversity, in which they in· clude early loss of mother (not necessarily the actual loss of mother, but the functional loss of mother), phys ical and sexual abuse as well as parental indiff erence or neglect (Brown et al. 1986) . Although the specifI city of these factors as leading to depression rather than other adolescent or adult psychopathology is debated, there is little question that these early developmental experiences do play a role in the onset of depression in numerous individuals (Bifulco et al. 1991 ). does the young child's inability to understand the ex act nature and extent of a brief separation lead to a per ception of "abandonment," which would not be expe rienced by an older child? Much more needs to be investigated with respect to early cognitive and emo tional development to tease out these issues.
We also do not know whether specifIc types of en vironmental stresses produce specifIc changes in corti cal and subcortical substrates. As the central nervous system develops, specifIc brain regions may have greater responsibility, but not necessarily greater plas ticity, in dealing with these additional "challenges." A desire among basic neuroscientists to investigate these questions in primate and rodent models has led to a variety of studies suggesting models for "human depression" involving learned helplessness and sepa ration paradigms (Koob et al. 1989) . Unfortunately, only recently has this research, although often elegant, in corporated a developmental perspective for such be havioral and neurochemical strategies (Kraemer 1992 ).
However, we still do not have sufficient information to be convinced of these interrelationships . We are left with abiding questions concerning whether these stresses provide a form of priming or early scarring with respect to he development of depression.
Just as we might also ask about the effects of diff erential environmental stresses, we might pose the question as to whether differential biologic endowment, such as temperamental attributes or genetic stability in rhythms, will determine a different response to the same stressor and thus diff erentially predispose to psy chopathology. We believe that queries along these lines need to be addressed, and appropriate experiments need to be devised. The second related question con cerning a form of "priming" is whether there is a nor mal range of biologic system fluctuations within which the biologic response to stresses can be absorbed and systems returned to homeostatic levels. Naturally, one would need to develop a template for the range and fluctuations of different systems, unless one assumes
The Mission of Therapeutics 171 a "universal" response range independent of the speci6.c biologic system. Then we are also left with the ques tion raised earlier as to whether the repeated experience of the same or of different stresses can modify the bio logic substrate. If we continue to envision this kind of interaction, we then begin to understand a priming ac tivity in which repeated stress can have an increasing impact representing compounding or eventually a depletion of coping ability. In this way, we can ask whether beginning dysregulation of biologic systems leads to environmental effects? Does such dysregula tion "create" life events or the perception that events are more stressful than earlier?
ROLE OF CHILDHOOD ADVERSITY AND CURRENT STRESSORS
The elegant work of Brown and coworkers (1986) has examined in detail childhood experience and the onset of depression. In this model, childhood adversity leads to an adverse adult life style, which, in the face of cur rent provoking agents, may lead to the onset of depres
sion. An example provided by the Brown group of the environmental pathway would be to posit the link be tween neglect by parents, premarital pregnancy, and early marriage to an undependable man leading to sub sequent marital difficulties. There is, however, an ad ditional strand through which childhood adversity might lead to a "cognitive bias," such as low self-esteem or negative self-evaluation. This cognitive bias, in turn, also provides an adult vulnerability that may indeed lead to the onset of depression. Brown and others have argued that on this "cognitive pathway," negative child hood experience is associated with a "helpless cogni tive set," which interferes with the development of suc cessful coping strategies and supportive relationships.
The lack of such support, in tum, increases risk for depression once a stressor arises. This view has been adapted by American investigators who have provided confrrmatory evidence for this pathway (Hammen
1992).
We now return to the question of whether dysregu lation of both biologic systems and psychosocial sys tems eventually exerts an effect on life events them selves. We have very little data to suggest how we would even begin to examine whether a priming of bio logic systems toward dysregulation has occurred, or whether the changes that have occurr ed in biologic sys tems have been followed by full recoveries or have pro duced scars that make the individual even more vul nerable to an initial episode of depression.
Recent data analyzed by Brown and colleagues (un published data) show that in adults, the presence of a severe event within 6 months of onset is unrelated to the severity of an initial episode of depression. The analysis of three different populations showed that both low-severity and high-severity fIrst onset is associated with approximately a 60% likelihood of a severe event in the 6 months prior to onset (Table 1) . However, if one examines a similar series of individuals who are experiencing their second or subsequent episode, the fIndings are different. In those individuals with a low level of severity (low melancholia score), 69% of these individuals had a severe life event within 6 months of depressive onset. On the other hand, among individu als with a high melancholia score, only 34% of individ uals had experienced a severe life event; a rate not differ ent from that observed in nondepressed subjects in the general population ( Table 2 ). This fInding is very con sistent with the hypothesis that Post and others have proposed with respect to differences between fIrst and subsequent episodes in terms of the likelihood of ex ternal provocation (Post 1992) .
The study by Brown and colleagues on the issue of whether melancholic! endogenous depression is more associated with severe life events has been followed up by a recent study in Pittsburgh on recurrent depression. Frank and colleagues (unpublished data) have shown that there is a signifIcant difference in the proportion of subjects experiencing a severe event in the 6 months before onset in individuals with research diagnostic criteria ROC endogenous subtype as compared with nonendogenous subtype (34% versus 56%, 'I} = 4 . 2, P = .04). Thus, we can tentatively conclude that life events occur quite frequently with the fIrst episode, regardless of severity; but, after the fIrst depressive epi sode they are not necessarily an associated feature of onset.
BIOLOGIC PATHWAYS AND CORRELATES
Although a number of other psychosocial factors could be discussed in detail, to simplify our argument, let us now turn briefly to the biologic domains. In examining the interaction between depression onset and under-NEUROPSYCHOPHARMACOLOGY 1 99 lying biologic changes, it is useful to pose several ques tions. Our initial question is when do biologic corre lates or stigmata present themselves in the lifetime course of depression? Perhaps an underlying assump tion of this question is whether biologic changes as sociated or not associated with adult depression are present in child and adolescent depression. For decades we assumed that there were few similarities between sadness in childhood and adolescence and what we con sidered major depression in adulthood. The introduc tion of OSM-III and OSM-III-R nosology resulted in a conceptual shift, suggesting that childhood and ado lescent depression shared most, if not all, the clinical features of adult depression. In the recent effort to diagnose childhood and adolescent disorders more ac curately, perhaps we have presumed that if the clinical picture in childhood and adulthood is similar, then the associated and even underlying psychobiology should also be quite comparable. For example, Puig-Antich suggested that the clinical picture in child and adoles cent depression would be reflected in similar biologic changes, particularly in sleep and neuroendocrine parameters (Puig-Antich 1986). However, his own early studies, as well as the results of others, have now pointed to the unlikeliness of neurobiologic similarity or constancy across the life span (Puig-Antich et al.
1982).
Thus, we are faced with a more intriguing set of questions. We need to take into account that there may be age-specifIc, gender-speciflc, developmentally phase specifIc factors that affect the features of the clinical pic ture, its level of severity and the neurobiologic changes. But, perhaps the key question is when does the frr st neurobiologic system demonstrate correlates with clin ical depression because it seems likely that there is a group of different neurobiologic systems, which reflect changes at different points in the life cycle.
The range of possible neurochemical and neurobio logic systems that could be implicated in mood dis orders is extensive, and recent reviews in childhood and as controls (Dahl et al. 1991) . The 24-hour cortisol is signiflcantly increased, especially during the presleep onset period in the early portion of the night (Fig. 1) . If one examines adolescent depressed patients for 24-hour cortisol, individuals with the high cortisol levels who also have short REM latency represent the majority of individuals with an elevated 24-hour cortisol (Fig.  2) . From these investigations, we can conclude that in adolescents, there appears to be an emergence of cor tisol changes in the hours before and after sleep onset (Fig. 3) . In comparable data on sleep parameters, Dahl and colleagues (1990) have shown that prolonged sleep onset difftculty is also associated with a reduced time to the fIrst REM period, so-called REM latency, which is frequently present in adolescent depressives. Never theless, despite these changes in the early phases of sleep, there does not appear to be any indication of re- duced slow-wave sleep in these adolescent depressives as compared to control subjects . In contrast, if we examine the sleep of young adults, there are consistent fIndings demonstrating sleep differ ences between young adult depressives and young con trols. Thus, it is only in the third decade that the sleep diff erences between controls and depressed patients be come marked. Recent investigations have conftrmed that this is true not just for the reduced REM latency 1991) (Fig. 4) . So, we can conclude that young adult depressives in their 20s show certain physiologic slee p &ndings that involve both REM and non-REM sleep ab normalities, As an important caveat, we need to real ize that the majority of these results are derived from cross-sectional investigations with most of the data col lected during the episode.
Although it has been well accepted that HP A axis changes occur in adult depressives (Sachar 1982) , only MODs AdoI(n=.27) recently has an extensive elegant reanalysis truly con firmed these fIndings. A metaanalysis by Van Cauter and colleagues (Van Cauter, personal communication, 1992) on samples derived from investigators around the world comparing depressed patients and agel gender matched controls indicates a 24-hour mean cortisol level that is signifIcantly elevated in depressed individuals irr espective of age. This elevation reflects a failure to suppress nighttime concentrations and an elevated na dir of cortisol levels compared to that of controls. The relative rhythm amplitude (mean circadian amplitude, i.e., amplitude in percent of 24-hour mean level) seems to be dampened, and there is clearly more pulsatile cor tisol variation. Finally, it appears that irrespective of age, the nadir occurs earlier in the depressed subjects. Th ese fIndings support the concept that the 24-hour rhythm of cortisol levels, as a highly reproducible marker of human circadian rhythmicity, is reflective of circadian abnormalities in depression.
In attempting to present an overall framework with respect to psychobiologic correlates in depression, our best estimate at this point is that both initial HP A (cor tisol) and REM sleep changes make their appearance between ages 10 and 20 years in individuals who are depressed and that slow-wave sleep changes and all night growth hormone decreases or such alterations in response to probe strategies may not be apparent until age 20 or above. So, it is necessary to assume that a different set of neurobiologic fIndings may be present dependent on the age of onset of the initial depressive episode (Fig. 5) .
As Post (1992) and others have indicated (Fig. 6 ), there appears to be a certain level of progression of stateltrait phenomena over the course of affective ill ness. It is fair to say that a number of state or episode related changes involve both physiologic sleep changes as well as a number of neuroendocrinelneuropeptide changes. They may also include an increased level of corticotropin-releasing hormone (CRH), which is re flected in changes in cortisol, as well as alterations in thyroid-releasing hormone and growth hormone dur ing the day. At the same time, reduced growth hormone Figure 6 . Progression of state-trait phenomenon over the course of affective illness SRIF = somatotropin releasing inhibiting factor (somatostatin). Adapted from Post 1992. is noted during the night, as well as reduced growth hormone to a clonodine challenge.
An alternative model for biologic changes has re cently been posed by us . Our own strategy has been to develop a model of the disor der that utilizes data on biologic correlates of recurrent depression. We have sought to emphasize a distinction between what will be referred to as Type 1 biologic correlates, or persistent features of the disorder, and Type 2 correlates, those associated with acute sym ptomatology ( Table 3 ) . It is suggested that Type 1 correlates might represent the very features that underlie the pathophysiology of the disorder . We believe that such correlates may repre sent measures of vulnerability to the disorder reflect ing the major impact of genetic or familial influences. Such features are observable even in individuals who have never had an episode but who are at risk. On the other hand, they may represent biologic scars, the re sidual effect of having had one or more episodes of depression, as well as effects of the aging process.
In contrast, Type 2 correlates are related to the more episodic features of the disorder. Such biologic corre lates may aid us in characterizing subtypes of depres sion, as well as in understanding speciftc diff erences between inpatients and outpatients. The characteriza tion of the stressors that lead to hospitalization and the decreased availability or viability of social support sys tems in the environment could be important factors. Furthermore, an understanding of gender diff erences in the experience and/or nature of such stressors and support systems may lead to a more sophisticated un derstanding of the acute episode and episodic biologic features.
Although these biologic changes are rather evident during the state of depression, a certain number of changes seem to be persistent beyond the episode it self (Type 1). These may include physiologic changes in sleep, as well as selected endocrine changes. For ex-
ample, at this point in time, an increasing consensus has led to the suggestion that reduced growth hormone is a prime example.
TREATMENT OUTCOME AS A WINDOW ON PATHOGENESIS
Because we believe that an improved understanding of the pathway to the initial episode of depression may be an important key to our overall concept of pathways to depression, we are emphasizing those factors that contribute to this initial episode. Furthermore, we also subscribe to the notion that the course of the frr st episode -onset and recovery and the impact of ther apeutic intervention-represent essential areas to in vestigate speciftcally. At the present time, our research efforts can be en hanced by understanding more about the role of and extent to which therapeutic intervention can playa role in treating the frrst episode. The frrst episode in many ways is very different from subsequent episodes; a level of profound dysregulation is usually present. We can ask the question of whether the therapeutic interven tion can completely reverse the dysregulation, in a sense, pushing the systems back into a normal range. Does normal recovery represent a return to homeosta sis and equilibrium and is there a "scar?" It is rather interesting to think about how the role of life events is perceived with respect to frrst episodes versus sub sequent episodes.
The basic problem with the two biologic models is exactly that: they are only biologic models and they do not incorporate any psychosocial factors, and nor they are not placed in a developmental context. The ques tion of how the next iterations of these models can be achieved is not an easy one, but numerous studies are now yielding clues to developing such an enriched model. Such fIndings can be derived from onset studi es A number of factors have been suggested as facili tators of recovery including the lack of a comorbid con dition such as a personality disorder, the presence of adequate social support systems, an increased level of self-esteem, the absence of or a reduction in chronic diffI culties, and also the presence of "fresh starts": that is, events offering hope or relief from prior strains. These features have been derived from a variety of studies in adult-onset depression, usually in patients between 18 and 64 years of age (Kupfer and Frank 1992) .
Recently, a study conducted by Karp, Frank, and colleagues (unpublished data) suggested that recovery in late-life depression may also be related to psychoso cial factors. In a series of over 100 elderly individuals suffering from at least their second lifetime episode of de pression who were treated with a combined drug (nortriptyline) and psychotherapy (interpersonal psy chotherapy) regimen, proportional hazards modeling (univariate and multivariate) showed that only four of the 27 clinical, demographic, and psychosocial variables examined were significant in predicting slower rate of res ponse to treatment: (1) the presence of a stress provoking agent, such as a severely threatening life event or an ongoing major difficulty, during the 6 months before onset of illness; (2) eccentric cluster per sonality features; (3) a low level of tangible social sup port; and (4) earlier age at frrst episode. Median time to response was increased by 2.5 weeks (from 6.5 to 9 weeks) in the presence of a stress-provoking agent.
These fIndings suggest a somewhat longer expected time to response among late-life patients with negative psychosocial circumstances.
It may also be useful to examine the specific treat ments for depression themselves as well as selected components of those treatments to help us provide data for further modeling. Because pharmacologic data is traditionally used exclusively for these "exercises," in an effort to achieve some level of balance, we will focus on aspects of nonpharmacologic treatments. In contrast, the rationale and approach of cogni tive therapy (Beck et al. 1979 ) is somewhat different.
It is based on the premise that depression is related to the absence of mastery or pleasure experiences in the To demonstrate how incomplete recovery or the persistence of subsyndromal symptoms relate to relapse and recurrence, Keller and colleagues (1992) showed that in bipolar patients, the presence of hypomanic sub syndromal features lead directly to the later occurrence of mania in the majority of cases (Table 4) . In situations in which the subsyndromal features were of a depres sive nature, the relapse into depression and/or mania was still increased compared to what would be likely based on naturalistic data sets.
One way of conceptualizing recurrent mood dis orders (or certainly bipolar disorder) has been suggested by Goodwin and Jamison (1990) who promoted an instability model of the pathophysiology of bipolar Adapted from Keller et al. 1992. disorder. Although their model included genetic vul nerability, stress, neurotransmitter dysregulation, cir cadian rhythm dysregulation, and the obvious presence of symptoms and behavioral disturbances, we believe that components related to rhythm dysregulation, be havior, and especially interpersonal stress can in fact be thought of as issues that must be addressed to achieve complete recovery. Indeed, our own notions on this matter, which point to the importance of social zeitgebers or social timekeepers to help stabilize rhythms, have been incorporated into a model of how the SeN or the biologic clock may function (Ehlers et al. 1988) . We argue that it depends on input not only from physical zeitgebers but social zeitgebers and that, in turn, then affects circadian effector systems (Fig. 7) .
This translates into an approach to treatment of in dividual patients that includes an emphasis on stabiliz ing social rhythms (Frank et al. unpublished data) . In a treatment approach currently being inves tigated at the University of Pittsburgh, Frank and col leagues (unpublished data) are utilizing both social rhythm stabilization and features of interpersonal psy chotherapy to develop a psychosocial intervention for bipolar disorder as an adjunct to pharmacologic treat ment, with the major aims of achieving complete recov ery from an episode and then sustaining the recovery. In an effort to stabilize social rhythms, the therapist'S &rst task is to &nd the patient's most unstable daily rhythms (e.g., a highly irregular sleep-wake schedule), then set goals for change in those rhythms, moving gradually and making certain that expectations for change are reasonable. The therapist also helps the pa tient identify triggers to rhythm disruption. Once those areas have been fully explored, the therapist inves tigates with the patient how to achieve the right bal ance in terms of how much rest, how much activity, and how much stimulation is ideal for that particular individual. The therapist and patient then develop strategies to maintain the balance and, with;n that main tenance plan, how to adapt to changes in routine, some of which may be planned and others unexpected.
In addition to rhythm stability and biological dys regulation, we believe that the appearance of subsyn dromal symptomatology following a complete recovery and incomplete recovery are important considerations. Once an individual has had one or two episodes of ei ther unipolar or bipolar disorder, it appears that there is a certain level of autonomy of the disorder. In fact, Post and others have suggested that continuing dys regulation, both biologic and nonbiologic, may reflect a more and more autonomous expression of the disor der. Another view, however, is that recurrences occur because of incomplete recovery. This may, in fact, rep resent a failure to regain homeostatis or a return only to the pre episode subclinical state. (Keller and others described a similar clinical state as "double depression." Keller and Shapiro, 1982.) Thinking about treatment success or failure from a developmental perspective may also provide a win dow on pathogenesis. For example, at what age do anti depressants begin to work? The current status of treat-ment research on antidepressants in prepubital and adolescent depression suggests that there is no defmi tive efficacy for antidepressant drugs. At this point, not enough treatment trials using the recent modifIcations ofIPT (Klerman and Weissman 1992) or cognitive ther apy (Wilkes et al. in press) in adolescent depression have been conducted to assess the efficacy for nonphar macologic intervention. Does the age at which anti depressants begin to work coincide with the age when biologic stigmata, on a consistent basis, is noted in clin ical depression? Hence, an important question may be to determine the age of onset for various biologic stigmata in depression because this, in turn, may give us clues with respect to treatment approaches in depression.
Another important issue that has been underplayed up to the present time is the role of gender differences in determining treatment strategies. Thus far, data does suggest that psychopharmacologic treatment appears to be fairly gender blind (Frank submitted) , as does cog nitive therapy (Thase et al. unpublished data) . How ever, with respect to both short-term and long-term IPT, there may indeed be gender differences in treatment efficacy.
Other questions that involve neurobiology and treatment approaches have to do with whether we can use biologic indictors to determine which patients will benefIt from maintenance treatment, both in terms of somatic treatment and nonsomatic treatments. These questions can be answered within the next decade as long as both biologic researchers work in an integrated fashion.
CONCLUSIONS
From this brief review on pathways to depression and selected treatment issues, we conclude that we are still faced with several major unresolved problems. These it is to help us better understand the disorders that we are treating.
